Lesson plan

Epcoritamab

Epcoritamab, sold under the brand name Epkinly among others, is a Bi-specific T-cell engager (BiTE) used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab. Epcoritamab was approved for medical use in the United States in May 2023, in the European Union in September 2023, and in Canada in December 2023.

Back to article

Article summary

Epcoritamab, sold under the brand name Epkinly among others, is a Bi-specific T-cell engager (BiTE) used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab. Epcoritamab was approved for medical use in the United States in May 2023, in the European Union in September 2023, and in Canada in December 2023.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.